Amundi Has $37.16 Million Position in Neurocrine Biosciences, Inc. $NBIX

Amundi lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 8.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 220,463 shares of the company's stock after purchasing an additional 16,826 shares during the quarter. Amundi owned 0.22% of Neurocrine Biosciences worth $37,156,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Bank of America Corp DE raised its position in Neurocrine Biosciences by 10.6% in the first quarter. Bank of America Corp DE now owns 583,827 shares of the company's stock valued at $76,913,000 after purchasing an additional 55,723 shares during the last quarter. ABN AMRO Bank N.V. bought a new stake in shares of Neurocrine Biosciences during the second quarter worth about $2,510,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in shares of Neurocrine Biosciences in the fourth quarter valued at approximately $1,866,000. SEB Asset Management AB bought a new position in Neurocrine Biosciences in the 1st quarter valued at approximately $10,483,000. Finally, Cetera Investment Advisers raised its holdings in Neurocrine Biosciences by 50.1% in the 1st quarter. Cetera Investment Advisers now owns 20,245 shares of the company's stock valued at $2,667,000 after buying an additional 6,756 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Wall Street Zen lowered shares of Neurocrine Biosciences from a "buy" rating to a "hold" rating in a report on Sunday, August 9th. The Goldman Sachs Group began coverage on shares of Neurocrine Biosciences in a research note on Tuesday, June 2nd. They set a "buy" rating and a $213.00 price target for the company. Weiss Ratings lowered shares of Neurocrine Biosciences from a "buy (b)" rating to a "buy (b-)" rating in a report on Tuesday. Guggenheim boosted their price objective on shares of Neurocrine Biosciences from $200.00 to $222.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a $198.00 price objective on shares of Neurocrine Biosciences in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $201.05.

Insider Transactions at Neurocrine Biosciences

In other news, insider Darin Lippoldt sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $179.60, for a total transaction of $1,796,000.00. Following the completion of the sale, the insider owned 54,729 shares of the company's stock, valued at $9,829,328.40. This trade represents a 15.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leslie Norwalk sold 1,250 shares of Neurocrine Biosciences stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $182.01, for a total transaction of $227,512.50. Following the completion of the sale, the director owned 1,588 shares of the company's stock, valued at $289,031.88. This represents a 44.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 40,188 shares of company stock valued at $7,118,633. Corporate insiders own 4.60% of the company's stock.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $156.57 on Friday. The firm has a market cap of $15.92 billion, a price-to-earnings ratio of 22.96, a PEG ratio of 0.73 and a beta of 0.38. Neurocrine Biosciences, Inc. has a 52-week low of $122.14 and a 52-week high of $186.12. The firm has a 50 day moving average price of $164.82 and a two-hundred day moving average price of $151.22.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, topping analysts' consensus estimates of $1.65 by $1.20. The business had revenue of $959.00 million during the quarter, compared to the consensus estimate of $891.16 million. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. Neurocrine Biosciences's quarterly revenue was up 39.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.65 earnings per share. As a group, equities research analysts predict that Neurocrine Biosciences, Inc. will post 7.25 EPS for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company develops therapies for conditions with significant unmet medical needs, using expertise in neuroscience and endocrine biology.

Its primary commercial product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington's disease.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.